Bagsværd, Denmark and Singapore, 16 October 2023 “ Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension...
PRINCETON, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced publication of the results of the BLOCK-CKD (Blood Pressure in Chronic Kidney Disease) phase 2b study of KBP-5074 by the peer-reviewed AHA journal, Hypertension. BLOCK-CKD achieved its primary endpoint with clinical and statistical significance: systolic blood pressure (SBP) was reduced in both 0.5 mg and 0.25 mg KBP-5074 cohorts by ?10.2 mm Hg and -7.0 mm Hg, respectively, compared to placebo. There were no reports of severe hyperkalemia or acute kidney injury with either dose of KBP-5074. The trial results of the BLOCK-CKD study paper were published online and will appear in the July 2021 print edition of the journal.
In early December, KBP Biosciences shared results for their BLOCK-CKD Phase IIb study, which has shown KBP-5074 could improve treatment for patients with severe chronic kidney disease (CKD), as it can lower blood pressure (BP) without increasing the risk of hyperkalemia (HK).
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a global, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet needs, today announced positive top-line results from its Phase 2b clinical trial (BLOCK-CKD) of its lead product candidate, KBP-5074. KBP-5074 is a potentially best-in-class, next-generation, non-steroidal mineralocorticoid receptor antagonist (MRA) being developed globally to initially treat patients with moderate-to-severe (Stage 3b/4) chronic kidney disease (CKD) and uncontrolled hypertension.
PRINCETON, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting, being held in a virtual format from October 22-25, 2020. Frederic Jaisser, Head of the Physiology Department, Cordeliers Research Center, Research Director, INSERM, is presenting an abstract entitled: “The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria with improved efficacy and safety compared to eplerenone.”
PRINCETON, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development and commercialization of innovative medicines for the global market, today announced that it has completed treatment of the final subject in BLOCK CKD (Blood Pressure in Chronic Kidney Disease), its Phase 2b study of lead product candidate, KBP-5074, a highly-selective and potent non-steroidal mineralocorticoid receptor antagonist (MRA), in patients with advanced (stage 3b/4) chronic kidney disease (CKD) and uncontrolled hypertension. The Company expects to announce top-line data from BLOCK CKD in the fourth quarter of 2020.
PRINCETON, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical stage biotechnology company dedicated to research, development and commercialization of innovative medicines for the global market, today announced the publication of the trial design for BLOCK CKD (Blood Pressure in Chronic Kidney Disease), the Company’s Phase 2b study of KBP-5074, a highly-selective and potent non-steroidal mineralocorticoid receptor antagonist (MRA) being studied as a treatment for uncontrolled hypertension in patients with advanced chronic kidney disease (CKD), in the peer-reviewed journal, Hypertension. The study design paper was published online, and will appear in the July 2020 print edition of the journal (DOI: 10.1161/HYPERTENSIONAHA.120.15199).
PRINCETON, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced the online publication of safety and pharmacokinetic (PK) results from a PK study of its lead product candidate, KBP-5074, a non-steroidal mineralocorticoid receptor antagonist (MRA), in patients with severe chronic kidney disease (CKD). A preprint was published in MedRxiv (https://doi.org/10.1101/2020.05.12.20053314), the preprint server for health sciences. KBP-5074, a highly selective and potent MRA, is in development to treat uncontrolled hypertension in patients with Stage 3B and 4 CKD.
PRINCETON, N.J., May 20, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical stage biotechnology company dedicated to research, development and commercialization of innovative medicines for the global market, today announced that it has completed patient enrollment of BLOCK CKD (Blood Pressure in Chronic Kidney Disease), its Phase 2b study of its lead product candidate, KBP-5074, a highly-selective and potent non-steroidal mineralocorticoid receptor antagonist (MRA), in patients with moderate-to-severe chronic kidney disease (CKD) and uncontrolled hypertension. The Company expects to report top line data from BLOCK CKD in the fourth quarter of 2020.